Press & News

The next generation biopharmaceuticals

Press releases 2013

2013-11-19

Interim Report – January to September 2013

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the Third Quarter 2013.[read more]

Older press releases

2013-11-05

Sobi announces phase I Complement Inhibitor program

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial today at the company’s Capital Markets Event in Stockholm.[read more]

2013-10-01

EU Funded Effort to Develop New Stroke Therapies

Solna, Sweden, October 1, 2013. The COUNTERSTROKE consortium led by researchers at Karolinska Institutet today initiates a six million Euro EU funded collaboration to develop novel therapeutics to treat stroke.[read more]

2013-09-17

New molecular imaging agents being developed for fluorescence-guided brain cancer surgery

Solna, Sweden, September 17, 2013. Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery.[read more]

Affibodys latest Press releases

2019-09-23

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi-...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q3 (Nov. 15, 2019)

Investor information